Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

New type 2 diabetes jab could slash number of injections to one a week

The treatment, also known as Onswik and made by Eli Lilly, is said to work as well as daily injections

The Independent UK · Aug 19

Firms face pressure from shifting demand after weight-loss pills approved

New research found 34% of Britons would consider taking weight loss medication in tablet form rather than injections.

Evening Standard · Aug 17

Hollywood’s “Getting Thinner” Trend Raises Concern As Jenna Ortega Becomes The Latest Celebrity To Worry Fans

"The next Ariana Grande."

Bored Panda · Aug 11

From analysis to the latest developments in health,
read the most diverse news in one place.

The Obesity Drug Race Moves Past Ozempic with a Shot Targeting Three Hormones

Eli Lilly's retatrutide produced up to 30.3% average weight loss in phase 3 trials. Approval is not expected before 2027 at the earliest.

Medical Daily · Aug 11

UK first in Europe to approve Eli Lilly oral weight loss drug

Britain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company Eli Lilly, the UK government has revealed. Eli Lilly's Mounjaro weight loss drug, like Wegovy, is injected. bcp/ajb/st

The Economic Times · Aug 11

Foundayo: The new weight loss pill approved for the UK

Foundayo has been approved for treating weight loss as well as type 2 diabetes

The Independent UK · Aug 11

Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription. Novo Nordisk's Wegovy pill also received approval for the UK market. The weight-loss drug market is seeing increased…

The Economic Times · Aug 11

Read news from The Economist, FT, and more,
with one subscription

New once-daily weight loss pill approved by the UK medicines regulator

The UK has become the first country in Europe to authorise orforglipron, known as Foundayo

The Independent UK · Aug 10

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.

Fortune · Aug 6

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

Barchart · Aug 6

Adding a Muscle Targeting Antibody to Semaglutide Cut Lean Mass Loss from 7.4% to 2.9% in a Phase 2 Trial

A 507-person trial found bimagrumab plus semaglutide protected lean mass while increasing fat loss. The drug remains investigational.

Medical Daily · Aug 6

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.

International Business Times · Aug 5

LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs

Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is driving LLY stock higher as well.

Barchart · Aug 5

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.

Benzinga · Aug 5

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times · Aug 5

Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing

Eli Lilly posted stronger-than-expected second-quarter earnings and revenue, boosted by surging demand for Zepbound and Mounjaro, while its newly launched obesity pill Foundayo made its first contribution to quarterly sales.

The Independent UK · Aug 5

Sales in weight-loss drug Mounjaro double amid surging market appetite

Eli Lilly’s chief executive David Ricks told investors that it was ‘building for the future’

Evening Standard · Aug 5

Mounjaro sales double this year as obesity drug boom prevails, says maker

The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.

Benzinga · Aug 4

Eli Lilly Could Swing $65.9 Billion After Earnings

Earnings are set to hit the tape in a tight window on Wednesday and the options market is already sketching out how much volatility traders are willing to pay for into the prints, according to Benzinga Pro.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times · Aug 4

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

Medical Daily · Aug 4

A Next-Generation Obesity Drug Has Been Released By Eli Lilly in Early Access to Select Patients

Eli Lilly will offer early access to the investigational obesity drug retatrutide after positive Phase 3 trials showed significant weight-loss results.

Medical Daily · Aug 4

Michigan Supreme Court Clears the Way for a State Investigation into Eli Lilly Insulin Pricing

Michigan's high court ruled 4-3 that the state may investigate Eli Lilly's insulin pricing. The decision authorizes a probe, not a finding of wrongdoing.

Marie Claire · Aug 3

What Is Retatrutide? The Next-Gen GLP-1 Poised to Become the Most In-Demand Peptide

A deep dive into Retatrutide shows promise—and a lot of danger.

Barchart · Aug 2

Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Medical Daily · Jul 28

Daily Oral Weight Loss Pill Outperformed Oral Semaglutide On Weight And Blood Sugar In Type 2 Diabetes

In a 1,698-person trial, orforglipron beat oral semaglutide on A1C and weight in type 2 diabetes. Here is what was measured and what was not.

The Economic Times · Jul 24

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.